Opinion: The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars
November 9, 2021
First Opinion The hurried push by Congress to address drug costs shouldn’t undermine the vast savings from generics and biosimilars By Dan Leonard Nov. 6, 2021
Reprints
Adobe
A mericans rightfully expect Congress to address the ever-increasing prices of brand-name prescription drugs.
Read the source article at statnews.com
2021-11-06 16:12:46